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159 Genotyping of Pseudomonas aeruginosa isolates can predict the
transition to chronic colonization in CF patients
P. Schelstraete1, P. Deschaght2, S. Van Daele1, F. Haerynck1, L. Van Simaey2,
M. Vaneechoutte2, F. De Baets1. 1Cystic Fibrosis Center, Ghent University
Hospital, Ghent, Belgium; 2Research Laboratory Microbiology, Ghent University,
Ghent, Belgium
Background: Chronic infection with P. aeruginosa results in a decreased life
expectancy of cystic ﬁbrosis patients. After a ﬁrst P. aeruginosa infection patients
go through periods of colonization. The time span between the ﬁrst positive sputum
culture and chronic colonization is variable and a period of uncertainty. In this study
we evaluated whether genotyping can predict the persistence of P. aeruginosa and
therefore predict the transition from colonization to chronic colonization.
Methods: From January 2002 till December 2008 sputa or nasopharyngeal aspirates
were cultured from 100 CF patients not chronically colonized according to the
European consensus criteria. Genotyping was carried out by RAPD-analysis. For
each patient, the genotypes of all available P. aeruginosa isolates obtained during
the study period, were compared.
Results: Seventeen patients became chronically colonized according to the Euro-
pean consensus criteria. For each of these 17 patients, all P. aeruginosa isolates
had an identical genotype. For 10 non chronically infected patients, the ﬁrst two
P. aeruginosa isolates showed the same genotype. For 7 of these 10 CF patients,
additional follow-up samples were available, whereby for 6 patients the P. aerug-
inosa isolate of the follow-up sample had the same genotype again, suggesting
persistence of the ﬁrst isolate.
Conclusions: Subsequent identical P. aeruginosa genotypes after a ﬁrst infection
predict a poor outcome of eradication treatment and may be used as an asset to
indicate persistence of the ﬁrst infecting strain leading to chronic lung colonization.
Supported by: Belgian Cystic Fibrosis Assocation and IWT Vlaanderen.
160 Analysis of proteins released from Pseudomonas aeruginosa
clinical and laboratory strains: effects of azithromycin
G. Bergamini1,4, P. Mauri2, C. Cigana1, D. Di Silvestre2, A. Di Palma2,
A. Bragonzi3, B.M. Assael1, C. Sorio4, P. Melotti1. 1Cystic Fibrosis Center,
Azienda Ospedaliera di Verona, Verona, Italy; 2Istituto Tecnologie Biomediche
CNR, Segrate, Milano, Italy; 3European Institute for Cystic Fibrosis Research,
Scientiﬁc Institute H.S. Raffaele, Milano, Italy; 4Department of Pathology, General
Pathology Section, University of Verona, Verona, Italy
Modulation Pseudomonas aeruginosa (Pa) virulence factors was suggested as
mechanism for azithromycin (AZM) beneﬁcial effects in CF patients. Our work
was aimed to study the regulation of proteins released by Pa strains after AZM
treatment.
Pa clinical isolates and PAO1 were grown overnight in aerobic conditions in the
presence or absence of AZM. We demonstrated that conditioned medium (CM)
from the clinical strain AA2, unlike CM from the laboratory strain PAO1, induced
a statistically signiﬁcant increase of about 3.6 and 2.7 times, respectively of IL-8 and
TNF-a mRNA, in CF airway epithelial cells. This induction was reduced of about
30% when AA2 was grown in the presence of AZM, suggesting that this macrolide
reduces Pa pathogenicity. Two-dimensional capillary chromatography–tandem mass
spectrometry (MudPIT) identiﬁed polypeptides released by PAO1 and AA2 in the
absence and presence of drug. 7 proteases were released from AA2 while only 1
from PAO1 with moderate down modulation of alkaline metalloprotease released
by AA2 in the presence of AZM as conﬁrmed by proteolytic activity assay.
Identiﬁcation of virulence factors might be facilitated by this combined approach
suggesting molecular targets for pharmacological intervention.
Supported by Italian Cystic Fibrosis Research Foundation(FFCgrant #17/2006);
Comitato Vicenza-Associazione Veneta Lotta contro la Fibrosi Cistica.
161 Lack of Differences in Mutant Prevention Concentration Rates
Between Cystic Fibrosis Pseudomonas aeruginosa Isolates in
Planktonic and Bioﬁlm Type of Growth
M. Garcia-Castillo1, M.C. Turrientes1, M.I. Morosini1, F. Baquero1, R. Canton1,
R. del Campo1. 1Service of Microbiology, Hospital Ramo´n y Cajal, Madrid, Spain
Objective: To compare the mutant prevention concentration (MPC) of Pseu-
domonas aeruginosa isolates from cystic ﬁbrosis (CF) patients using both plank-
tonic and bioﬁlm type of growth.
Patients and Methods: Forty-two P. aeruginosa isolates from sputum samples
of 10 CF patients attending our hospital during 2004–2008 were studied. Genetic
relatedness was performed by PFGE-XbaI. MPC for ciproﬂoxacin, ceftazidime,
imipenem, and tobramycin were calculated in LB-plates adding 500 ml of an
overnight culture. Bioﬁlm formation was developed along 3 days on the surface
of nitrocellulose ﬁlter disks. For the bioﬁlm-MPC experiment, all bacteria growth
in the nitrocellulose ﬁlter was seeded. After plates incubation (37.C, 48 h), the
MPC value was the ﬁrst concentration without colonies. All experiments were
performed in triplicate and results correspond to the mean value. The P. aeruginosa
PAO1 (normomutator) and PAO1deltamutS (hipermutator) strains were included as
controls.
Results: Eighteen PFGE patterns were found among the 42 isolates, being 3
pulsotypes present in two different patients. The MPC mean values of the 42
strains with planctonic or bioﬁlm growth were 16/8 mcg/ml for ciproﬂoxacin,
1024/512 mcg/ml for ceftazidime, 64/64 mcg/ml for imipenem, and 32/32 mcg/ml
for tobramycin. The same phenomenon was observed for the controls strains.
Conclusion: The MPC values for ciproﬂoxacin, ceftazidime, imipenem, and to-
bramycin of CF-P. aeruginosa isolates growing in planktonic conditions were similar
to that obtained in bioﬁlm-growing conditions.
162 Antibiotics sensitivity in mucoid and non mucoid Pseudomonas
aeruginosa isolates from cystic ﬁbrosis patients
L. Cariani1, G. Deﬁlippi1, D. Costantini1, C. Colombo1, M.L. Garlaschi1,
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Lung infections caused by Pseudomonas aeruginosa (PA) increase morbidity and
mortality in cystic ﬁbrosis (CF) patients. Antibiotic regimen selected for therapy
depends on in vitro pattern of the strain of PA.
We evaluated the prevalence of susceptibility of PA and mucoid PA strains isolated
from CF sputum of patients followed at Regional CF Centre of Milan.
The laboratory information system was retrospectively reviewed to determine the
sensitivity pattern of PA and mucoid PA to eleven antipseudomonal antibiotics from
2001 to 2008. The antimicrobial susceptibilities were determined by a standardized and
automated method (MicroScan, Siemens H.D.); results were interpreted according to
Clinical and Laboratory Standards (CLSI doc. M100-S18) guidelines.
PA and mucoid PA susceptibility data are shown in the table.
Pseudomonas aeruginosa strains show a better susceptibility in comparison to mucoid
PA strains. Over the last decade only mucoid PA demonstrates a trend in increasing
resistance to antibiotics.
These positive ﬁndings may be related to strict segregation policy adopted in our centre.
PA/mucoid PA strains sensitivity (%)
Antibiotic 2001 2002 2003 2004 2005 2006 2007 2008
PA muc PA muc PA muc PA muc PA muc PA muc PA muc PA muc
ATM 55 56 55 56 52 62 47 56 52 64 45 66 57 62 66 51
CAZ 64 66 60 67 60 70 54 64 57 74 53 70 59 66 69 57
CIP 53 44 51 43 57 46 52 41 56 51 53 43 53 40 53 35
LVX 53 52 52 50 57 51 54 49 56 52 53 48 58 50 58 44
NN 65 76 65 73 64 73 58 67 62 71 62 70 68 72 71 64
MEM 80 79 76 76 76 78 70 74 73 85 73 80 77 80 79 74
IPM 66 59 61 58 63 58 58 59 63 65 65 64 70 63 71 57
PIP 56 62 54 63 64 62 58 58 60 64 55 75 66 72 79 63
TIM 59 48 57 46 69 56 63 56 67 66 60 78 70 78 80 69
tot n
strains
1067 843 1208 897 1165 722 1000 561 1166 431 1214 667 1191 624 1302 733
tot pz 501 515 539 569 548 572 591 610
